Matthew Brian Hartz, MD, MPH | |
3366 Oakdale Ave N, Ste 605, Robbinsdale, MN 55422-5700 | |
(763) 520-2940 | |
(763) 520-2943 |
Full Name | Matthew Brian Hartz |
---|---|
Gender | Male |
Speciality | Critical Care (intensivists) |
Experience | 25 Years |
Location | 3366 Oakdale Ave N, Robbinsdale, Minnesota |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1518948066 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 33786 (Iowa) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
North Memorial Health | Robbinsdale, MN | Hospital |
Maple Grove Hospital | Maple grove, MN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
North Memorial Health Care | 0042123028 | 483 |
Respiratory Consultants Pa | 6204736853 | 17 |
News Archive
D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).
Two new UC Davis studies add scientific evidence that hunters' lead ammunition often finds its way into carrion-eating birds, such as eagles and turkey vultures.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.
Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.
› Verified 2 days ago
Entity Name | Respiratory Consultants Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1356439277 PECOS PAC ID: 6204736853 Enrollment ID: O20040112000044 |
News Archive
D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).
Two new UC Davis studies add scientific evidence that hunters' lead ammunition often finds its way into carrion-eating birds, such as eagles and turkey vultures.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.
Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.
› Verified 2 days ago
Entity Name | North Memorial Health Care |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1851344907 PECOS PAC ID: 0042123028 Enrollment ID: O20040122000470 |
News Archive
D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).
Two new UC Davis studies add scientific evidence that hunters' lead ammunition often finds its way into carrion-eating birds, such as eagles and turkey vultures.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.
Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Matthew Brian Hartz, MD, MPH 3366 Oakdale Ave N, Ste 605, Robbinsdale, MN 55422-5700 Ph: (763) 520-2940 | Matthew Brian Hartz, MD, MPH 3366 Oakdale Ave N, Ste 605, Robbinsdale, MN 55422-5700 Ph: (763) 520-2940 |
News Archive
D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).
Two new UC Davis studies add scientific evidence that hunters' lead ammunition often finds its way into carrion-eating birds, such as eagles and turkey vultures.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.
Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.
› Verified 2 days ago
Dr. Alok Maheshwari, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-581-5400 Fax: 763-581-5401 | |
Ethan Michael Fruechte, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Suite 200, Robbinsdale, MN 55422 Phone: 763-581-5400 Fax: 763-520-2099 | |
Matthew Nolan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3366 Oakdale Ave N Ste 401, Robbinsdale, MN 55422 Phone: 763-520-2940 | |
Jerrold Martin Stempel, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3366 Oakdale Ave N, Suite 315, Robbinsdale, MN 55422 Phone: 763-520-7900 Fax: 763-520-7989 | |
Chike Uchenna Anthony Obi, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-581-5400 Fax: 763-581-5401 | |
Dr. John Manion, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3435 West Broadway, Suite 1065, Robbinsdale, MN 55422 Phone: 763-520-1137 Fax: 763-520-1976 | |
Andrew Joob, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5200 |